keyword
MENU ▼
Read by QxMD icon Read
search

hepatitis C new treatments

keyword
https://www.readbyqxmd.com/read/29779403/lipids-glucose-and-iron-metabolic-alterations-in-chronic-hepatitis-c-after-viral-eradication-comparison-of-the-new-direct-acting-antiviral-agents-with-the-old-regimens
#1
Joana Rita Carvalho, José Velosa, Fátima Serejo
BACKGROUND: Hepatitis C virus (HCV) is a unique virus which interacts with cholesterol, iron and insulin metabolism. There is limited data on the effects of direct-acting antiviral agents (DAAs) on metabolic profiles. We aimed at evaluating the behavior of metabolic risk factors of chronically HCV-infected patients after sustained virologic response (SVR), comparing the outcomes with the new DAAs versus the old treatment regimen Peg-interferon ± ribavirin. METHODS: A total of 178 patients who achieved SVR and completed one year of follow-up were prospectively included in this study: group 1 with 105 patients treated with DAAs and group 2 with 73 patients treated with old regimens...
May 20, 2018: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29778258/new-treatments-have-changed-the-game-hepatitis-c-treatment-in-primary-care
#2
REVIEW
Shelley N Facente, Katie Burk, Kelly Eagen, Elise S Mara, Aaron A Smith, Colleen S Lynch
In the pre-direct-acting antiviral era, hepatitis C virus (HCV) treatments were complex and largely managed by hepatologists, gastroenterologists, and infectious disease physicians. As direct-acting antivirals have driven up demand for treatment, the relative scarcity of these specialists has created a bottleneck effect, resulting in only a fraction of HCV-infected individuals offered treatment. The San Francisco Health Network is a safety net system of care. Its intervention was designed to be sustainable and scalable; with minimal time commitments for training providers, primary care-based HCV treatment increased 3-fold in a period of just over 3 years...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29778257/localized-us-efforts-to-eliminate-hepatitis-c
#3
REVIEW
Annette Gaudino, Bryn Gay, Clifton Garmon, Mike Selick, Reed Vreeland, Katie Burk, Emalie Huriaux, Shelley N Facente, Annie Luetkemeyer, Phil Waters, Camilla S Graham
The United States has national plans for the elimination of hepatitis C virus but much of US health care is organized on the state level and requires local solutions. This article describes the plans developed by New York, Massachusetts, and the city/county of San Francisco for hepatitis C virus elimination. Coalitions capitalize on existing resources and advocate for new resources to address barriers in hepatitis C virus care. Although each coalition has distinct plans, all share a commitment to groups that are disproportionately affected and are at risk for being excluded from advances in hepatitis C virus treatment and cure...
June 2018: Infectious Disease Clinics of North America
https://www.readbyqxmd.com/read/29775725/anti-hepatitis-c-virus-activity-and-synergistic-effect-of-nymphaea-alba-extracts-and-bioactive-constituents-in-liver-infected-cells
#4
Sidra Rehman, Usman Ali Ashfaq, Bushra Ijaz, Sheikh Riazuddin
BACKGROUND: Without an effective vaccine, hepatitis C virus (HCV) remains a global threat, inflicting 170-300 million carriers worldwide at risk of cirrhosis and hepatocellular carcinoma (HCC). Though various direct acting antivirals have been redeemed the hepatitis C treatment, a few restraints persist including possible side effects, viral resistance emergence, excessive cost which restricts its availability to a common person. HYPOTHESIS: There is no preventive HCV vaccine available today so the discovery of potent antiviral natural flora and their bioactive constituents may help to develop preventive cures against HCV infection...
May 15, 2018: Microbial Pathogenesis
https://www.readbyqxmd.com/read/29774607/impact-of-current-and-scaled-up-levels-of-hepatitis-c-prevention-and-treatment-interventions-for-people-who-inject-drugs-in-three-uk-settings-what-is-required-to-achieve-the-who-s-hcv-elimination-targets
#5
Zoe Ward, Lucy Platt, Sedona Sweeney, Vivian D Hope, Lisa Maher, Sharon Hutchinson, Norah Palmateer, Josie Smith, Noel Craine, Avril Taylor, Natasha Martin, Rachel Ayres, John Dillon, Matthew Hickman, Peter Vickerman
AIMS: To estimate the impact of existing high-coverage needle and syringe provision (HCNSP, defined as obtaining more than one sterile needle and syringe per injection reported) and opioid substitution therapy (OST) on hepatitis C virus (HCV) transmission among people who inject drugs (PWID) in three UK settings and to determine required scale-up of interventions, including HCV treatment, needed to reach the World Health Organization (WHO) target of reducing HCV incidence by 90% by 2030...
May 17, 2018: Addiction
https://www.readbyqxmd.com/read/29774107/clinical-outcome-of-hepatocellular-carcinoma-can-be-predicted-by-the-expression-of-hepatic-progenitor-cell-markers-and-serum-tumour-markers
#6
Satoshi Seino, Atsunori Tsuchiya, Yusuke Watanabe, Yuzo Kawata, Yuichi Kojima, Shunzo Ikarashi, Hiroyuki Yanai, Koji Nakamura, Daisuke Kumaki, Masaaki Hirano, Kazuhiro Funakoshi, Takashi Aono, Takeshi Sakai, Jun Sakata, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Toshifumi Wakai, Shuji Terai
The high heterogeneity of hepatocellular carcinomas (HCCs) complicates stratification of HCC patients for treatment. Therefore, it is necessary to establish a comprehensive panel of HCC biomarkers related to tumour behaviour and cancer prognosis. Resected HCCs from 251 patients were stained for hepatic progenitor cell (HPC) markers epithelial cell adhesion molecule (EpCAM), neural cell adhesion molecule (NCAM), delta-like 1 homolog (DLK1), and cytokeratin 19 (CK19). Staining patterns were analysed for their prognostic association with relapse-free survival and overall survival...
April 24, 2018: Oncotarget
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#7
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29768546/first-wave-protease-inhibitors-for-hepatitis-c-genotype-1-treatment-a-real-life-experience-in-brazilian-patients
#8
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli
INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center...
March 2018: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29761585/hepatitis-b-virus-hbv-reactivation-the-potential-role-of-direct-acting-agents-for-hepatitis-c-virus-hcv
#9
REVIEW
Jason T Blackard, Kenneth E Sherman
Hepatitis C virus (HCV) is known to inhibit hepatitis B virus (HBV) replication in patients with HBV/HCV coinfection. Reactivation of HBV in patients treated for HCV with direct-acting agents (DAAs) has emerged recently as an important clinical consideration. A growing number of case reports and case series support the association between new HCV treatments and HBV reactivation. Yet, very little is known about the specific viral characteristics that facilitate reactivation as functional characterization of the reactivated HBV has been conducted only rarely...
May 15, 2018: Reviews in Medical Virology
https://www.readbyqxmd.com/read/29761292/-chronic-hepatitis-b-and-d-delta-current-and-future-treatments
#10
REVIEW
N Wortmann, C Höner Zu Siederdissen, M Cornberg
BACKGROUND: Worldwide, hepatitis B virus (HBV) infection is among the 30 leading causes of death, despite effective vaccination and therapeutic options. Chronic hepatitis delta (coinfection with hepatitis D virus) leads to a rapid disease progression. AIMS: Based on current international guidelines and studies, an overview about present and future therapeutic options for chronic hepatitis B and delta is provided. RESULTS: Therapy with nucleoside or nucleotide analogues leads to nearly complete HBV DNA suppression, which is associated with regression of liver fibrosis and a lower risk for the development of hepatocellular carcinoma...
May 14, 2018: Der Internist
https://www.readbyqxmd.com/read/29760542/mouse-models-for-investigating-the-underlying-mechanisms-of-nonalcoholic-steatohepatitis-derived-hepatocellular-carcinoma
#11
REVIEW
Kazuki Takakura, Tsunekazu Oikawa, Yoichi Tomita, Yusuke Mizuno, Masanori Nakano, Chisato Saeki, Yuichi Torisu, Masayuki Saruta
As the incidence of hepatocellular carcinoma (HCC) caused by infection with the hepatotropic viruses hepatitis B and hepatitis C decreases, greater attention has become focused on HCC caused by nonalcoholic steatohepatitis (NASH), an advanced form of nonalcoholic fatty liver disease which has shown increasing prevalence in correspondence with the overall increase in metabolic syndrome over the recent decades. Several clinical population studies have shown a positive relationship between NASH and HCC, while also providing initial insights into the underlying mechanisms of HCC development from NASH...
May 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29757684/an-account-of-the-real-life-hepatitis-c-management-in-a-single-specialized-viral-hepatitis-treatment-centre-in-egypt-results-of-treating-7042-patients-with-7-different-direct-acting-antiviral-regimens
#12
Mohamed El Kassas, Mohamed Alboraie, Dalia Omran, Mohamed Salaheldin, Mohamed Naguib Wifi, Mohamed ElBadry, Adel El Tahan, Sameera Ezzat, Enass Moaz, Amir M Farid, Heba Omar, Mahmoud Abouelkhair, Shimaa Afify, Kadry Elsaeed, Yehia Shazly, Wahid Doss, Gamal Esmat
BACKGROUND: A large Egyptian treatment program for HCV was launched in 2014 after the introduction of direct-acting antiviral agents (DAAs). This program depended mainly on establishing specialized independent centres for HCV treatment. These centres represent the major strengths in the Egyptian model of care, as they provide integrated care for HCV patients and have enabled Egypt to treat more than one million patients in 3 years. The New Cairo Viral Hepatitis Treatment Center (NCVHTC) is an example of these specialized centres...
May 14, 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29757491/evaluation-of-a-hepatitis-c-clinical-care-coordination-program-s-effect-on-treatment-initiation-and-cure-a-surveillance-based-propensity-score-matching-approach
#13
Regan Deming, Mary M Ford, Miranda S Moore, Sungwoo Lim, Ponni Perumalswami, Jeffrey Weiss, Brooke Wyatt, Shuchin Shukla, Alain Litwin, Sheila Reynoso, Fabienne Laraque
Hepatitis C (HCV) is a viral infection that if left untreated can severely damage the liver. Project INSPIRE was a three year HCV care coordination program in New York City (NYC) that aimed to address barriers to treatment initiation and cure by providing patients with supportive services and health promotion. We examined whether enrollment in Project INSPIRE was associated with differences in HCV treatment and cure compared with a demographically similar group not enrolled in the program. INSPIRE participants in 2015 were matched with a cohort of HCV-infected persons identified in the NYC surveillance registry, using full optimal matching on propensity scores and stratified by INSPIRE enrollment status...
May 14, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29753376/effectiveness-of-sofosbuvir-ribavirin-and-peg-ifn%C3%AE-2a-in-the-treatment-of-na%C3%A3-ve-egyptian-patients-with-chronic-hepatitis-c-virus-genotype-4
#14
Fatma Abdallah, Gehad Mohamed, Mohsen Ibrahim, Mokhtar El Tarabily
BACKGROUND: Egypt is one of the largest epidemic areas of hepatitis C virus (HCV) in the world. Its prevalent genotype is 4 with a majority of subtype 4a. In 2013, the Food and Drug Administration approved a new direct-acting antiviral drug (sofosbuvir) to treat patients with chronic HCV infection. In Egypt, the patients are already being treated with sofosbuvir in conjunction with ribavirin and pegylated interferon alfa-2a (PEG-IFNα-2a) for 12 weeks since 2015. The present study was planned to explain the efficacy of this treatment regimen against the HCV genotype 4a in Egyptian patients and its pretreatment predictive factors of virological response...
May 2018: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/29746724/efficacy-and-safety-of-elbasvir-grazoprevir-fixed-dose-in-the-management-of-polytreated-hcv-patients-evidence-from-real-life-clinical-practice
#15
Benedetto Caroleo, Lidia Colangelo, Maria Perticone, Giovambattista De Sarro, Luca Gallelli
Chronic hepatitis C virus (HCV) infection represents a global public health challenge, and new drugs have been authorized for its treatment. In this study, we evaluated both the clinical efficacy and safety of elbasvir-grazoprevir fixed-dose combination in HCV patients. We performed a prospective single-blind study on patients admitted to the Regional Center for HCV Treatment of the University of Catanzaro from March 1, 2017, to December 31, 2017, in patients >30 years old with a history of chronic HCV infection...
May 10, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29744934/modelling-how-reversal-of-immune-exhaustion-elicits-cure-of-chronic-hepatitis-c-after-the-end-of-treatment-with-direct-acting-antiviral-agents
#16
Subhasish Baral, Rahul Roy, Narendra M Dixit
A fraction of chronic hepatitis C patients treated with direct-acting antivirals (DAAs) achieved sustained virological responses (SVR), or cure, despite having detectable viremia at the end of treatment (EOT). This observation, termed EOT+ /SVR, remains puzzling and precludes rational optimization of treatment durations. One hypothesis to explain EOT+ /SVR, the immunologic hypothesis, argues that the viral decline induced by DAAs during treatment reverses the exhaustion of cytotoxic T lymphocytes (CTLs), which then clear the infection after treatment...
May 9, 2018: Immunology and Cell Biology
https://www.readbyqxmd.com/read/29743456/-short-term-sustained-virological-response-in-a-patient-with-liver-cirrhosis-hepatitis-c-and-declining-hepatic-spare-ability-during-treatment-with-direct-acting-antivirals
#17
Hitoshi Mori, Hiroaki Takaya, Tadashi Namisaki, Ryuichi Noguchi, Junichi Hanatani, Miki Kaneko, Kenichiro Seki, Yasushi Okura, Mitsuteru Kitade, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji
A 75-year-old female patient with liver cirrhosis and hepatitis C was treated with direct-acting antivirals (DAA) (Sofosbuvir+Ledipasvir). The hepatitis C virus (HCV) -RNA level decreased to negative 4 weeks after the start of the treatment. Six weeks later, she developed ascites and showed declining hepatic spare ability. Accordingly, DAA treatment was stopped. She was started on furosemide 20mg/day and spironolactone 50mg/day. After 7 days, she started taking tolvaptan 7.5mg/day because furosemide and spironolactone proved to be ineffective...
2018: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/29743015/mortality-trends-among-people-with-hepatitis-b-and-c-a-population-based-linkage-study-1993-2012
#18
Maryam Alavi, Jason Grebely, Behzad Hajarizadeh, Janaki Amin, Sarah Larney, Matthew G Law, Jacob George, Louisa Degenhardt, Gregory J Dore
BACKGROUND: This study evaluated cause-specific mortality trends including liver-related mortality among people with a hepatitis B virus (HBV) and hepatitis C virus (HCV) notification in New South Wales, Australia. METHODS: Notifications 1993-2012 were linked to cause-specific mortality records 1993-2013. RESULTS: Among 57,929 and 92,474 people with a HBV and HCV notification, 4.8% and 10.0% died since 1997. In early 2010s, 28% and 33% of HBV and HCV deaths were liver-related, 28% and 17% were cancer-related (excluding liver cancer), and 5% and 15% were drug-related, respectively...
May 9, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29739095/distribution-of-il28b-rs12979860-and-rs8099917-genotypes-in-patients-with-chronic-hepatitis-c-virus-infection-in-tianjin-china
#19
Kunyan Qiao, Congdoanh Trieu, Zhixiao Huo, Yanan Du, Wei Hou
BACKGROUND: Two single-nucleotide polymorphisms (SNPs) rs12979860 (C/T) and rs8099917 (T/G), near the interleukin 28B (IL28B, also known as IFN lambda-3, IFNL3) gene, have a strong association with both spontaneous and treatment-induced hepatitis C virus (HCV) clearance. IL28B polymorphisms have shown a marked differential distribution with regional and ethnic variation. The study aimed to investigate the distribution of IL28B rs12979860 and rs8099917 genotypes in patients with chronic hepatitis C (CHC) in Tianjin, China...
April 1, 2018: Clinical Laboratory
https://www.readbyqxmd.com/read/29738698/corticosteroids-reduce-risk-of-death-within-28-days-for-patients-with-severe-alcoholic-hepatitis-compared-with-pentoxifylline-or-placebo-a-meta-analysis-of-individual-data
#20
Alexandre Louvet, Mark R Thursz, Dong Joon Kim, Julien Labreuche, Stephen Atkinson, Sandeep Singh Sidhu, John G O'Grady, Evangelos Akriviadis, Emmanouil Sinakos, Robert L Carithers, Marie-José Ramond, Willis C Maddrey, Timothy R Morgan, Alain Duhamel, Philippe Mathurin
BACKGROUND & AIMS: We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis. We compared the effects of the treatments on survival for 28 days or 6 months, and response to treatment based on the Lille model. METHODS: We searched PubMed for randomized controlled trials of pharmacologic therapy for severe alcoholic hepatitis...
May 5, 2018: Gastroenterology
keyword
keyword
76658
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"